Jason M. Marks J.D. Net Worth

The estimated Net Worth of Jason M. Marks is at least 19.7 千$ dollars as of 19 August 2022. Mr Marks owns over 33,334 units of Amarin Corp stock worth over 19,667$ and over the last 3 years he sold AMRN stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr D AMRN stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Amarin Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 33,334 units of AMRN stock worth 19,667$ on 19 August 2022.

The largest trade he's ever made was exercising 33,334 units of Amarin Corp stock on 19 August 2022 worth over 19,667$. On average, Mr trades about 6,667 units every 0 days since 2021. As of 19 August 2022 he still owns at least 33,334 units of Amarin Corp stock.

You can see the complete history of Mr Marks stock trades at the bottom of the page.

Mr. Jason M. Marks J.D. biography

Jason M. Marks J.D. is the Chief Legal Officer & Corp. Sec. at Amarin Corp.

How old is Mr D?

Mr D is 44, he's been the Chief Legal Officer & Corp. Sec. of Amarin Corp since . There are 17 older and no younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.

What's Mr D's mailing address?

Jason's mailing address filed with the SEC is C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4, 440 US HIGHWAY 22, NESS ZIONA, L3, 7414003.

Insiders trading at Amarin Corp

Over the last 13 years, insiders at Amarin Corp have traded over 25,876,836$ worth of Amarin Corp stock and bought 581,426 units worth 751,974$ . The most active insiders traders include John F Thero、Steven B Ketchum、David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of 29,442$. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth 102,400$.

What does Amarin Corp do?

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.

Complete history of Mr Marks stock trades at Amarin Corp、BiomX Inc

Amarin Corp executives and stock owners

Amarin Corp executives and other stock owners filed with the SEC include:

• John Thero,
  President, Chief Executive Officer, Director
• Stephen Ketchum,
  President - Research and Development, Senior Vice President, Chief Scientific Officer
• Joseph Kennedy,
  Executive Vice President, General Counsel, Secretary, Strategic Initiatives
• Aaron Berg,
  Senior Vice President, Chief Commercial Officer
• Michael Kalb,
  Chief Financial Officer, Senior Vice President, Assistant Secretary
• Joseph Zakrzewski,
  Non-Executive Independent Director
• Dr. Steven B. Ketchum Ph.D.,
  Pres of R&D, Exec. VP and Chief Scientific Officer
• Dr. Steven B. Ketchum,
  Pres of R&D, Sr. VP and Chief Scientific Officer
• Michael W. Kalb,
  CFO, Sr. VP & Assistant Sec.
• Aaron D. Berg,
  Exec. VP & Pres of U.S.
• Elisabeth Schwartz,
  IR Contact Officer
• Jan van Heek,
  Non-Executive Independent Director
• David Stack,
  Non-Executive Independent Director
• Kristine Peterson,
  Non-Executive Independent Director
• Patrick O'Sullivan,
  Non-Executive Independent Director
• Lars Ekman,
  Non-Executive Independent Chairman of the Board
• Alan J. Wills B.A., BA (Zoology), M.B.A., MBA,
  Exec. VP of Corp. Bus. Devel.
• Jason M. Marks J.D.,
  Chief Legal Officer & Corp. Sec.
• Karim Mikhail,
  Pres, CEO & Director
• Donna Pasek,
  Sr. VP of HR
• Rami Daoud,
  Sr. VP of Corp. Devel.
• Alina Kolomeyer,
  Director of Communications
• Daniel S. Dunham,
  Sr. VP & Chief Pharmaceutical Compliance Officer
• Healthcare Partners Ltd. Fo...,
  Director
• Louis Iii Sterling,
  
• Oliver O'connor,
  
• Paul Cohen,
  
• Kostas D Odysseas,
  
• Mark Di Paolo,
  
• Steven B Ketchum,
  Chief Scientific Officer
• Murray Stewart,
  
• Karim Mikhail,
  President and CEO
• Jason M. Marks,
  EVP,Chief Global Legal Officer
• Alfonso G Zulueta,
  
• Erin S. Enright,
  
• Thomas Charles Reilly,
  EVP and CFO
• Geraldine Murphy,
  
• Adam Mark Berger,
  
• Diane E. Sullivan,
  
• Olsen Per Wold,
  Director
• Keith Horn,
  
• Jonathan Provoost,
  EVP, Chief Legal Officer
• Patrice Eadon Bonfiglio,
  
• Patrick Holt,
  President and CEO